Harborview Injury Prevention and Research Center   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Seattle WA United States (1985)

Organization Overview

First Clinical Trial
1991
NCT00004817
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Harborview Injury Prevention and Research Center

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Communicable Diseases (Phase 3)

Craniocerebral Trauma (Phase 3)

Epilepsy (Phase 3)

Epilepsy, Post-Traumatic (Phase 3)

Fasciitis (Phase 3)

Fasciitis, Necrotizing (Phase 3)

Fournier Gangrene (Phase 3)

Gangrene (Phase 3)

Infections (Phase 3)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Seizures (Phase 3)

Sepsis (Phase 3)

Soft Tissue Infections (Phase 3)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 14